The trial investigated the stage IB-IIIA intention-to-treat (ITT) population, which included NSCLC patients with EGFR/ALK alterations, as well as the PD-L1-positive subpopulation (stages II-IIIA). This evidence concerns the gene ALK and non-small cell lung carcinoma.